Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
Date:9/19/2011

mia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); uncertainties related to the regulatory process in the United States, Europe and Japan; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the FDA website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in KRX-0401 (Perifosine) Phase 3 Refractory Advanced Colorectal Cancer Study
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
4. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
5. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
6. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
7. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
9. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
10. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
11. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the nine months ended September 30, 2014.  ... dollars and presented under International Financial Reporting Standards ... it has wound down its Phase 2 diabetic ... will continue to investigate  other potential use indications ...
(Date:11/28/2014)... 2014 The American Association of ... School of Nursing with a very prestigious award ... The 2014 Innovations in Professional Nursing Education Award ... and supports them as they re-envision traditional models ... AACN’s annual meeting in Washington, D.C. to Meredith ...
(Date:11/28/2014)... The report provides qualitative insights on key ... of the market, in order to provide information about ... and market sizes for each sub-segment of the market ... It also includes analysis of the company profiles of ... financial performances, product portfolios, and developments of each company. ...
(Date:11/27/2014)... The Europe Thermal Protective Clothing ... provide crucial revenue forecasts. It estimates the market ... a CAGR of 7.5%, from 2013 to 2018. ... Thermal Protective Clothing market report for a glimpse ... by various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
Breaking Biology Technology:iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update 2iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update 3iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update 4American Association of Colleges of Nursing honors Fairfield University’s School of Nursing for Re-envisioning Nursing Education 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3
... venture capitalist in San Francisco or Boston, and youre on the ... Wisconsin. Everything looks right: The management team is in place, the ... ,But then a lawyer steps into the room, clears her ... lien law. Better not write that check, she says, until you ...
... state government information technology consolidation projects bound to be ... for the State of Wisconsin, has indicated the problems ... for large state projects. He has plenty of support ... are cost overruns, implementation delays, and outright failures really ...
... Madison, Wis. - GenTel BioSciences, Inc., ... $1.2 million Phase II SBIR grant from the National ... less painful diagnosis of respiratory allergies. , ,An estimated ... allergies, and current diagnostic tests are uncomfortable, especially for ...
Cached Biology Technology:Why repealing the shareholder wage lien law makes sense 2Why repealing the shareholder wage lien law makes sense 3State IT failures are not inevitable 2State IT failures are not inevitable 3State IT failures are not inevitable 4State IT failures are not inevitable 5GenTel gets federal grant to develop allergy test 2GenTel gets federal grant to develop allergy test 3
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... almost every plant species on the Iberian Peninsula had ... and Taraxacum lacianense , two dandelions from ... This finding confirms Spain,s privileged position as a hotbed ... now in Spain. It depends on the complexity of ...
... - William T. Talman, MD, President of the Federation ... Barack Obama for his continuing support for science and ... on research," Talman stated. In a letter to ... critical investmenteven during a time of unprecedented budgetary constraintswill ...
... More than a third of coral reef fish species ... climate change on coral reefs, a new scientific study has ... from individual locations, while they continue to persist elsewhere across ... international team of marine scientists has found that a third ...
Cached Biology News:2 new plants discovered in Spain 2Extinction predictor 'will help protect coral reefs' 2Extinction predictor 'will help protect coral reefs' 3
...
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... a microprocessor controlled, high speed filter ... exceptionally smooth operation make the Lambda ... fluorescence microscopy, ratio imaging, spectrophotometry, visual ... and accurate aperture positioning. The Lambda ...
Biology Products: